文献速递眼底病与葡萄膜炎青光眼

葡萄膜炎及其解剖亚型中青光眼、糖皮质激素反应和高眼压的发病率与患病率

Incidence and Prevalence of Glaucoma, Corticosteroid Response, and Ocular Hypertension in Uveitis and its Anatomical Subtypes.
PubMed 文献 · Am J Ophthalmol · 2025-06-04

基于TriNetX美国数据库的回顾性研究,识别出30,681例葡萄膜炎相关青光眼患者。2013至2022年间,葡萄膜炎人群中10年内15.5%发生青光眼,累积发病率为每10万人5例,累积患病率为每10万人27例,且发病率和患病率呈下降趋势。前部合并中间葡萄膜炎患者的青光眼相对发生率最高。

要点

  • 葡萄膜炎人群中10年内15.5%发生青光眼,累积发病率每10万人5例,累积患病率每10万人27例。
  • 前部合并中间葡萄膜炎患者的葡萄膜炎相关青光眼发生率最高(20.3%)。
  • 2013至2022年间,葡萄膜炎相关青光眼的发病率和患病率下降。

核心结论

  • 自2013年以来,葡萄膜炎相关青光眼的发病率和患病率持续下降。
  • 前部合并中间葡萄膜炎患者相较于其他葡萄膜炎亚型具有最高的青光眼相对发生率。

研究设计与样本

  • 回顾性研究,基于TriNetX美国协作网络数据库(包含超过1亿患者病历)。
  • 研究对象为同一日或葡萄膜炎发病后诊断为葡萄膜炎合并青光眼、高眼压或糖皮质激素反应(依据ICD-10编码)的患者。
  • 共识别30,681例葡萄膜炎相关青光眼患者,平均年龄67岁(SD=19,95%CI 66.8-67.2岁),55.0%为女性(n=16,875,95%CI 54.4-55.9%),50.7%为白人(n=15,555,95%CI 50.1-51.3%)。
  • 主要结局为2013至2022年间的累积和年度发病率与患病率,并按葡萄膜炎解剖位置进行亚组分析。

主要发现

  • 葡萄膜炎人群中10年内15.5%发生青光眼(n=30,681,95%CI 15.3-15.6%)。
  • 2013至2022年间,葡萄膜炎相关青光眼的累积发病率为每10万人5例,累积患病率为每10万人27例。
  • 前部合并中间葡萄膜炎患者的葡萄膜炎相关青光眼发生率最高(n=529;20.3%,95%CI 18.8-21.9%),其次为前部葡萄膜炎(n=20,849;16.4%,95%CI 16.2-16.7%)、全葡萄膜炎(n=48;11.6%,95%CI 8.5-14.7%)、眼内炎(n=273;11.3%,95%CI 10.9-11.7%)、中间葡萄膜炎(n=173;10.0%,95%CI 8.6-11.5%)和后部葡萄膜炎(n=1,579;8.2%,95%CI 7.8-8.6%)。
  • 前部合并中间葡萄膜炎患者的高眼压发生率(n=465;17.9%,95%CI 16.4-19.3%)和糖皮质激素反应发生率(n=279;10.7%,95%CI 9.5-11.9%)也最高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Uveitic glaucoma represents one of the most serious, sight-threatening complications of ocular inflammatory disorders. In this study, we assessed the cumulative and yearly prevalence and incidence of uveitic glaucoma in the TriNetX United States (US) Collaborative Network, a database composed of over 100 million patient medical records. DESIGN: Incidence, Prevalence, and Trend study. PARTICIPANTS: Subjects with uveitic glaucoma in the TriNetX database. METHODS: A retrospective study of a uveitic-glaucoma cohort, identified with patients having both ICD-10 codes of uveitis and glaucoma, ocular hypertension, or corticosteroid response diagnosed on the same day or after the onset of uveitis, was conducted using the TriNetX US database. Demographic information as well as cumulative and yearly incidence and prevalence of uveitic glaucoma were determined. MAIN OUTCOME MEASURES: Cumulative and yearly incidence and prevalence of uveitic glaucoma, between 2013-2022. A sub-analysis of uveitic glaucoma by uveitis anatomic location was also conducted. RESULTS: 30,681 patients with uveitic glaucoma were identified. The average age of the cohort at presentation was 67 years (SD = 19, 95% CI 66.8-67.2 years); 55.0% (n = 16 875, 95% CI 54.4-55.9%) were female and 50.7% (n = 15 555, 95% CI 50.1-51.3%) were Caucasian. Among the uveitis population, 15.5% of patients developed glaucoma in the 10-year time period (n = 30 681, 95% CI 15.3-15.6%). The cumulative incidence of uveitic glaucoma was 5 per 100 000 and the cumulative prevalence was 27 per 100,000 between 2013 and 2022. During the study period, the incidence and prevalence of uveitic glaucoma decreased. Patients with both anterior and intermediate uveitis (n = 529; 20.3%, 95% CI 18.8-21.9%) had the highest rates of uveitic glaucoma, followed by anterior (n = 20 849; 16.4%, 95% CI 16.2-16.7%), panuveitis (n = 48; 11.6%, 95% CI 8.5-14.7%), endophthalmitis (n = 273; 11.3%, 95% CI 10.9-11.7%), intermediate (n = 173; 10.0%, 95% CI 8.6-11.5%), and posterior (n = 1579; 8.2%, 95% CI 7.8-8.6%). Anterior and intermediate uveitis patients also had the highest rates of ocular hypertension (n = 465; 17.9%, 95% CI 16.4-19.3%) and corticosteroid response (n = 279; 10.7%, 95% CI 9.5-11.9%). CONCLUSIONS: Since 2013, the incidence and prevalence rates of uveitic glaucoma have been decreasing. Patients with both anterior and intermediate uveitis patients had the highest relative rates of glaucoma compared to other uveitis subtypes.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Marshall RF, Lee D, Thorne JE, et al. Incidence and Prevalence of Glaucoma, Corticosteroid Response, and Ocular Hypertension in Uveitis and its Anatomical Subtypes. Am J Ophthalmol. 2025. PMID: 40480344. doi:10.1016/j.ajo.2025.05.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。